Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results

Pfizer reported stronger-than-expected second-quarter results, with adjusted EPS of 78 cents and revenue of $14.65 billion, both surpassing Wall Street estimates. Consequently, the company raised its full-year adjusted profit guidance to $2.90-$3.10 per share, attributing the improvement to ongoing cost cuts and solid business performance. This revised outlook incorporates a $1.35 billion one-time charge from a licensing deal and accounts for existing tariffs and potential drug price changes, as Pfizer aims for $7.7 billion in savings by 2027 to offset the decline in its Covid-related business.

Analysis

Pfizer delivered a robust second quarter, significantly outperforming Wall Street expectations with an adjusted EPS of 78 cents against a consensus of 58 cents, and revenue of $14.65 billion surpassing the $13.56 billion forecast. This performance, representing a 10% year-over-year revenue increase, prompted management to raise its full-year adjusted profit guidance to a range of $2.90 to $3.10 per share. The improved outlook is underpinned by the successful execution of an aggressive cost-cutting strategy, now targeting $7.7 billion in savings by the end of 2027, designed to offset the decline from its Covid-related business. Critically, the company has already incorporated known headwinds into its forecast, including a $1.35 billion one-time charge for a Q3 licensing deal and the anticipated impact of existing tariffs and potential drug pricing pressures from the U.S. administration. While the company maintained its 2025 revenue target, its ability to raise near-term profit guidance amidst these external pressures highlights operational resilience and effective capital management.

Key Decisions for Investors

• The significant earnings beat and upward revision of full-year profit guidance signal strong operational momentum, warranting a review of positions for potential upside.
• Investors should closely monitor political rhetoric and policy developments concerning U.S. drug pricing and trade tariffs, as any escalation beyond what Pfizer has already priced into its outlook could introduce downside risk.
• The progress of the $7.7 billion cost-saving initiative is a key performance indicator to track in coming quarters, as its successful execution is central to the company's post-Covid strategic pivot and long-term value creation.